Diabetes Therapy SCIE

國際簡稱：DIABETES THER 參考譯名：糖尿病治療

主要研究方向：Medicine-Endocrinology, Diabetes and Metabolism 非預(yù)警期刊審稿周期： 6 Weeks

《糖尿病治療》(Diabetes Therapy)是一本由Springer Healthcare出版的以Medicine-Endocrinology, Diabetes and Metabolism為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q3 JCR分區(qū)
144 年發(fā)文量
2.8 IF影響因子
開放是否OA
25 H-index
2010 創(chuàng)刊年份
12 issues per year 出版周期
English 出版語言

Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

[ 查看全部 ]

投稿咨詢加急咨詢

Diabetes Therapy期刊信息

ISSN：1869-6953
出版語言：English
是否OA：開放
E-ISSN：1869-6961
出版地區(qū)：ENGLAND
是否預(yù)警：否
出版商：Springer Healthcare
出版周期：12 issues per year
創(chuàng)刊時(shí)間：2010
開源占比：0.9965
Gold OA文章占比：99.79%
OA被引用占比：1
出版國人文章占比：0.11
出版撤稿占比：0
研究類文章占比：82.64%

Diabetes Therapy CiteScore評價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

6.9

0.938

0.999

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Internal Medicine	Q1	35 / 167	79%
大類：Medicine 小類：Endocrinology, Diabetes and Metabolism	Q2	68 / 244	72%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Diabetes Therapy中科院評價(jià)數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	4區(qū)

Diabetes Therapy JCR評價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	97 / 186	48.1%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	103 / 186	44.89%

Diabetes Therapy歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Diabetes Therapy中國學(xué)者發(fā)文選摘

1、Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
Author: Liu, Lei; Ruan, Zhen; Ung, Carolina Oi Lam; Zhang, Yawen; Shen, Yang; Han, Sheng; Jia, Ruxu; Qiao, Jingtao; Hu, Hao; Guo, Lixin

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 93-107. DOI: 10.1007/s13300-022-01336-7
2、Application of the PDCA Cycle for Managing Hyperglycemia in Critically Ill Patients
Author: Chen, Jie; Cai, Wenchao; Lin, Feng; Chen, Xiaochu; Chen, Rui; Ruan, Zhanwei

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 293-301. DOI: 10.1007/s13300-022-01334-9
3、Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study
Author: Huang, Rongdong; Liu, Xiaoqin; Xie, Fangqin; Li, Junrong; Tang, Zhangbin; Wu, Yuying; Zhou, Peicong; Zhang, Dongjuan

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 139-151. DOI: 10.1007/s13300-022-01343-8
4、Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
Author: Wang, Shun-hua; Shao, Wei; Jiang, Qiu-hui; Zheng, Xuan-ling; Shen, Qing-bao; Lin, Xiao-yan; Zhang, Qiao-qing; Zhang, Lu-lu; Shi, Xiu-lin; Wang, Wen-gui; Li, Xue-jun

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 167-178. DOI: 10.1007/s13300-022-01342-9
5、Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
Author: Wang, Hong; Xie, Xiaoya; Zu, Quannan; Lu, Ming; Chen, Rongfa; Yang, Zhiren; Gao, Yongqiang; Tang, Zhangui

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 47-61. DOI: 10.1007/s13300-022-01350-9
6、Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
Author: Jiang, Zhiming; Liu, Le; Bundhun, Pravesh Kumar

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 387-399. DOI: 10.1007/s13300-022-01354-5
7、Independent and Joint Associations of Age, Pre-pregnancy BMI, and Gestational Weight Gain with Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
Author: Lee, Chee S.; Zhu, Shuqi; Wu, Qi; Hu, Ying; Chen, Yunyan; Chen, Danqing; Liang, Zhaoxia

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 363-375. DOI: 10.1007/s13300-022-01352-7
8、Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study
Author: Zhou, Jingjing; Jiang, Shimin; Li, Zhongxin; Li, Wenge

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 3, pp. 497-506. DOI: 10.1007/s13300-022-01361-6